| 2024-04-08 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Pres., R&D, and CMO | 2,676 0.0126% | $245.99 | $658,258 | -6.74% | |
| 2024-04-05 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Pres., R&D, and CMO | 27,506 0.1312% | $243.36 | $6.69M | -4.39% | |
| 2024-04-05 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Pres., R&D, and CMO | 22,228 0.1058% | $242.84 | $5.4M | -4.39% | |
| 2024-04-04 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Pres., R&D, and CMO | 18,537 0.0888% | $242.91 | $4.5M | -3.64% | |
| 2024-04-04 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Pres., R&D, and CMO | 13,339 0.0636% | $241.81 | $3.23M | -3.64% | |
| 2024-04-03 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Pres., R&D, and CMO | 27,845 0.1399% | $245.14 | $6.83M | -4.99% | |
| 2024-04-03 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Pres., R&D, and CMO | 6,839 0.0342% | $244.24 | $1.67M | -4.99% | |
| 2018-06-11 | Sale | Madrigal Pharmaceuticals, Inc. MDGL | Chief Medical Officer, EVP R&D | 73,526 0.5365% | $287.46 | $21.14M | -50.82% |